Rationale for the inclusion of alpha-adrenergic blockade in benign prostatic hyperplasia treatment guidelines

Research output: Contribution to journalArticle

2 Scopus citations


The effectiveness and safety of a-adrenergic blockade for the treatment of BPH has been demonstrated in large-scale, randomized, placebo-controlled, multicenter trials. Good patient compliance, low failure or retreatment rates, and cost-effectiveness have also been shown. Moreover, therapeutic success has been independent of the healthcare provider or venue. Accordingly, both the Agency for Health Care Policy and Research (AHCPR) and the 3rd International Consultation on BPH have recognized α1-specific adrenergic receptor blockers as a reasonable treatment alternative for men with symptomatic BPH.

Original languageEnglish (US)
Pages (from-to)40-48
Number of pages9
JournalEuropean urology
Issue numberSUPPL. 1
StatePublished - Jan 1 1996



  • Alpha-blocker
  • Benign prostatic hyperplasia
  • Treatment guidelines

ASJC Scopus subject areas

  • Urology

Cite this